Revolution Medicines (RVMDW) Expected to Announce Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMDW) is anticipated to post its results after the market closes on Wednesday, August 5th. Analysts expect Revolution Medicines to post earnings of ($2.0426) per share and revenue of $1.7730 million for the quarter.

Revolution Medicines Trading Up 10.3%

NASDAQ RVMDW traded up $0.91 on Tuesday, hitting $9.75. 425,704 shares of the stock were exchanged, compared to its average volume of 120,958. Revolution Medicines has a 52-week low of $0.16 and a 52-week high of $10.12. The company’s 50-day moving average price is $7.92 and its two-hundred day moving average price is $4.71.

Revolution Medicines Company Profile

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.